Research programme: Cancer therapeutics - PUMC Pharmaceutical CompanyAlternative Names: 801; AD1
Latest Information Update: 06 Jan 2016
At a glance
- Originator PUMC Pharmaceutical Company
- Class Colchicum alkaloids
- Mechanism of Action DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Jan 2016 Preclinical trials in Cancer in China (unspecified route)